Literature DB >> 16323717

Sedation and analgesia-prescribing patterns in terminally ill patients at the end of life.

Luis Vitetta1, David Kenner, Avni Sali.   

Abstract

The extensive use of sedative and analgesic medication at the end of life is often controversial due to the perception that death may be hastened as a result of progressive drug escalation. Physician attitudes toward prescribing medication in this setting vary, resulting in widely differing prescribing patterns for patients with advanced cancer. This investigation attempted to identify overall prescribing patterns and variation in the use of sedation and analgesia in an inpatient hospice setting at the end of life. A retrospective case review was undertaken of 102 consecutive patients who died in a palliative care hospice. A detailed review of medication prescription, with particular attention to sedation and analgesia in the last week of life, was performed. The review revealed that regular sedation was prescribed in 68 percent of the patients. Almost two-thirds of the patients began regular sedation on admission or within seven days of admission. Although survival was higher in patients who received regular sedation (mean, 36.5 days) versus those that did not (mean, 17 days), the difference was not significant (p = 0.1). Overall, regular sedation with moderate dose increases was observed. In patients prescribed morphine from the time of admission, morphine oral equivalents increased from a mean of 111 mg on admission to a mean of 346 mg at time of death for a mean escalation of 311 percent. The mean duration of admission was 26 days with an opioid-escalation index of 12 percent per day. Survival is a multifactorial phenomenon and was unrelated to the level of analgesia in this cohort. Findings showed that sedation dose increased modestly toward the end of life, and that the increase was not associated with a significant reduction in survival. Further there was no significant impact on survival related to an individual physician's prescribing pattern at the end of life. These results suggest that, in the institution where the review was conducted, neither sedation nor individual variation in physician prescribing habits in terminally ill patients was associated with hastening of death. Overall, the amount of sedative drugs required for adequate symptom control during terminal care was moderate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16323717     DOI: 10.1177/104990910502200601

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  11 in total

1.  Changes in medication profile among patients with advanced cancer admitted to an acute palliative care unit.

Authors:  David Hui; Zhijun Li; Gary B Chisholm; Neha Didwaniya; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2014-08-16       Impact factor: 3.603

Review 2.  Clarifying delirium management: practical, evidenced-based, expert recommendations for clinical practice.

Authors:  Scott A Irwin; Rosene D Pirrello; Jeremy M Hirst; Gary T Buckholz; Frank D Ferris
Journal:  J Palliat Med       Date:  2013-03-12       Impact factor: 2.947

3.  Palliative sedation in advanced cancer patients hospitalized in a specialized palliative care unit.

Authors:  Santiago Parra Palacio; Clara Elisa Giraldo Hoyos; Camilo Arias Rodríguez; Daniel Mejía Arrieta; John Jairo Vargas Gómez; Alicia Krikorian
Journal:  Support Care Cancer       Date:  2018-03-29       Impact factor: 3.603

Review 4.  Palliative pharmacological sedation for terminally ill adults.

Authors:  Elaine M Beller; Mieke L van Driel; Leanne McGregor; Shani Truong; Geoffrey Mitchell
Journal:  Cochrane Database Syst Rev       Date:  2015-01-02

5.  The Attitudes of Indian Palliative-care Nurses and Physicians to Pain Control and Palliative Sedation.

Authors:  Joris Gielen; Harmala Gupta; Ambika Rajvanshi; Sushma Bhatnagar; Seema Mishra; Arvind K Chaturvedi; Stef Van den Branden; Bert Broeckaert
Journal:  Indian J Palliat Care       Date:  2011-01

6.  The use of opioids at the end of life: the knowledge level of Dutch physicians as a potential barrier to effective pain management.

Authors:  Mette L Rurup; Christiaan A Rhodius; Sander D Borgsteede; Manon Sa Boddaert; Astrid Gm Keijser; H Roeline W Pasman; Bregje D Onwuteaka-Philipsen
Journal:  BMC Palliat Care       Date:  2010-11-12       Impact factor: 3.234

7.  Palliative sedation for terminally ill cancer patients in a tertiary cancer center in Shanghai, China.

Authors:  Xiaoli Gu; Wenwu Cheng; Menglei Chen; Minghui Liu; Zhe Zhang
Journal:  BMC Palliat Care       Date:  2015-03-15       Impact factor: 3.234

8.  Propofol-based palliative sedation in terminally ill children with solid tumors: A case series.

Authors:  Evelina Miele; Mastronuzzi Angela; M Giuseppina Cefalo; Francesca Del Bufalo; M Debora De Pasquale; Serra Annalisa; Gian Paolo Spinelli; De Sio Luigi
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.889

9.  Palliative Sedation in Advanced Cancer Patients: Does it Shorten Survival Time? - A Systematic Review.

Authors:  B Barathi; Prabha S Chandra
Journal:  Indian J Palliat Care       Date:  2013-01

10.  Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients.

Authors:  Linda G Franken; Brenda C M de Winter; Anniek D Masman; Monique van Dijk; Frans P M Baar; Dick Tibboel; Birgit C P Koch; Teun van Gelder; Ron A A Mathot
Journal:  Br J Clin Pharmacol       Date:  2017-10-26       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.